Farglitazar
Systematic (IUPAC) name | |
---|---|
N-(o-benzoylphenyl)-O-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethyl]-L-tyrosine | |
Clinical data | |
Pregnancy category |
|
Legal status |
|
Identifiers | |
CAS Number | 196808-45-4 |
ATC code | None |
PubChem | CID 170364 |
IUPHAR/BPS | 2672 |
ChemSpider | 148961 |
UNII | 3433GY7132 |
ChEMBL | CHEMBL107367 |
Chemical data | |
Formula | C34H30N2O5 |
Molar mass | 546.612 g/mol |
| |
| |
(what is this?) (verify) |
Farglitazar is a peroxisome proliferator-activated receptor agonist which is being developed by GlaxoSmithKline for the treatment of hepatic fibrosis. It is currently in phase II clinical trials.
References
This article is issued from Wikipedia - version of the Sunday, August 23, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.